PCN95 Pharmacoeconomic Analysis of Direct Medical Costs Associated With the Treatment of Advanced Esophago-Gastric Cancer Therapy With Xeloda or 5-Fluorouracil (5-FU) Regimens- Implications for Health Care Utilisation in Australia
Abstract
Authors
G. Tran S. Hack A. Kerr L. Stokes P. Gibbs T. Price C. Todd